This article is more than 5 years old. Information may no longer be current.

Allergan pharmaceutical sales up 13% from 2004 first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Allergan’s net sales during the first quarter of 2005 were $527.2 million, with pharmaceutical sales increasing 12.6% compared with the first quarter of 2004, the company announced in a press release.

Pharmaceutical sales were $298 million during the quarter. The company attributed a portion of the sales increase to European Union approval of glaucoma treatment Combigan (brimonidine tartrate, timolol). Glaucoma medication Lumigan (bimatoprost) increased sales to $62 million in the quarter, up from $53.5 million in the year-ago period.

Glaucoma medications Alphagan (brimonidine 0.2%), Alphagan P (brimonidine 0.15%) and Combigan posted sales of $66.7 million, which represented a decrease of $2.6 million from the first quarter of 2004.

Dry eye medication Restasis (cyclosporine) increased sales from $21.3 million in the first quarter of 2004 to $37.3 million during the first quarter of 2005.

Botox (botulinum toxin type A) generated sales of $176.3 million during the quarter.

A sizable restructuring charge affected overall results, the company said in the release. Additionally, introduction of two other glaucoma drugs will be delayed in the United States, the company said; the Food and Drug Administration has issued a conditional approval for Alphagan Z, Allergan noted, related to manufacturing issues that should be resolved shortly. The FDA has also requested additional clinical studies before approval of Combigan.